Hungarian drugmaker Richter Gedeon Nyrt. (RICHTER.BU) said Thursday it plans to move schizophrenia drug cariprazine into late-stage testing early...
Hungarian drug maker Richter Gedeon Nyrt. (RICHTER.BU) and Forest Laboratories Inc. (FRX) announced positive drug test results on cariprazine...
-- Once-a-day tablet Daxas(R) (roflumilast) is a first-in-class treatment under development targeting inflammation, the underlying cause of...
India's Glenmark Pharmaceuticals Ltd. (532296.BY) and U.S.-based Forest Laboratories Inc. (FRX) said Wednesday their experimental drug failed to...
India's Glenmark Pharmaceuticals Ltd. (532296.BY) and U.S.-based Forest Laboratories Inc. (FRX) said Wednesday their drug to treat a breathing...
U.K. pharmaceutical company AstraZeneca PLC (AZN.LN) Wednesday said it inked a deal to develop and sell an experimental anti-infection treatment...
NEW YORK, Aug. 10 /PRNewswire-FirstCall/ -- -- Forest Laboratories acquires exclusive commercialisation rights to Daxas in the United...
Forest Laboratories Inc.'s (FRX) fiscal first-quarter profit rose a better-than-expected 8.2% as sales of its Namenda treatment for Alzheimer's...
DALLAS, June 22 /PRNewswire/ -- BeaconEquity.com announces the availability of stock alerts on today's active stocks. Stock alerts highlight...
Forest Laboratories Inc. (FRX) reported encouraging results from two late-stage studies of its ceftaroline treatment for bacterial pneumonia and...
Sales of Wyeth's (WYE) new antidepressant Pristiq are nowhere near the drug maker's 2006 peak annual forecast of more than $2 billion, due to...
Pharmaceutical companies agreed to pay an additional $89 million to Alabama in settlement of litigation against 72 companies accused of defrauding...
Indian pharmaceutical company Jubilant Organosys Ltd. (530019.BY) Tuesday said a unit has signed a drug research agreement with the U.K.'s...
Spanish drug maker Laboratorios Almirall SA (ALM.MC) has started additional studies on a drug for chronic obstructive pulmonary disease, or COPD...
Forest Laboratories Inc.'s (FRX) fiscal fourth-quarter net income fell 46%, partly reflecting $170 million the maker of name-brand and generic...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.